Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 13,712 Shares

Key Points

• Stoke Therapeutics' General Counsel, Jonathan Allan, sold 13,712 shares at an average price of $15.00, substantially reducing their ownership by 41.12%.
• The company's stock price rose by 6.1% to $18.21 following recent trading activity, with a current market cap of approximately $998 million.
• Stoke Therapeutics reported earnings of ($0.40) per share, exceeding analyst expectations, despite revenue falling short at $13.82 million against estimates of $31.51 million.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 13,712 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total value of $205,680.00. Following the transaction, the general counsel directly owned 19,631 shares in the company, valued at $294,465. This trade represents a 41.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Stoke Therapeutics Stock Up 6.1%

STOK traded up $1.04 during midday trading on Friday, reaching $18.21. The company had a trading volume of 1,967,052 shares, compared to its average volume of 798,108. The business has a 50-day moving average of $12.41 and a two-hundred day moving average of $10.11. The company has a market cap of $997.91 million, a P/E ratio of 21.42 and a beta of 1.15. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $18.45.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. The firm had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. On average, equities research analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

STOK has been the topic of several research reports. HC Wainwright dropped their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Wedbush boosted their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday. Chardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Finally, Jefferies Financial Group assumed coverage on Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 target price on the stock. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Stoke Therapeutics has an average rating of "Buy" and a consensus target price of $25.17.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in shares of Stoke Therapeutics by 0.9% during the 1st quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock worth $904,000 after acquiring an additional 1,148 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock valued at $162,000 after purchasing an additional 1,149 shares in the last quarter. Graham Capital Management L.P. raised its position in Stoke Therapeutics by 8.5% during the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after purchasing an additional 1,453 shares in the last quarter. BNP Paribas Financial Markets raised its position in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock valued at $48,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC raised its position in Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock valued at $1,021,000 after purchasing an additional 1,791 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.